Fiera Capital Corp Makes New $18.44 Million Investment in Viking Therapeutics, Inc. (NASDAQ:VKTX)

Fiera Capital Corp acquired a new stake in Viking Therapeutics, Inc. (NASDAQ:VKTX) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 291,318 shares of the biotechnology company’s stock, valued at approximately $18,443,000. Fiera Capital Corp owned 0.26% of Viking Therapeutics at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Oak Ridge Investments LLC bought a new position in Viking Therapeutics in the 3rd quarter valued at about $837,000. Nvwm LLC acquired a new position in shares of Viking Therapeutics in the third quarter valued at approximately $999,000. Nepsis Inc. bought a new position in shares of Viking Therapeutics during the third quarter worth approximately $11,251,000. CWM LLC lifted its holdings in Viking Therapeutics by 70.6% during the 2nd quarter. CWM LLC now owns 1,518 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 628 shares during the last quarter. Finally, Raymond James & Associates boosted its stake in Viking Therapeutics by 43.2% in the 3rd quarter. Raymond James & Associates now owns 441,590 shares of the biotechnology company’s stock valued at $27,957,000 after purchasing an additional 133,144 shares during the period. Institutional investors and hedge funds own 76.03% of the company’s stock.

Insider Buying and Selling at Viking Therapeutics

In other news, Director Sarah Kathryn Rouan sold 11,000 shares of the business’s stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $80.89, for a total transaction of $889,790.00. Following the sale, the director now directly owns 9,500 shares in the company, valued at approximately $768,455. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Viking Therapeutics news, Director J Matthew Singleton sold 20,786 shares of Viking Therapeutics stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $57.53, for a total transaction of $1,195,818.58. Following the transaction, the director now directly owns 9,500 shares of the company’s stock, valued at approximately $546,535. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Sarah Kathryn Rouan sold 11,000 shares of the company’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $80.89, for a total value of $889,790.00. Following the completion of the sale, the director now owns 9,500 shares in the company, valued at $768,455. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 527,473 shares of company stock worth $37,225,498. 4.70% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

VKTX has been the topic of several research reports. StockNews.com upgraded shares of Viking Therapeutics to a “sell” rating in a research note on Tuesday, October 15th. HC Wainwright raised their target price on shares of Viking Therapeutics from $90.00 to $102.00 and gave the stock a “buy” rating in a report on Monday, November 4th. JPMorgan Chase & Co. began coverage on Viking Therapeutics in a research note on Wednesday, September 11th. They issued an “overweight” rating and a $80.00 price target for the company. Raymond James raised their price objective on Viking Therapeutics from $116.00 to $118.00 and gave the stock a “strong-buy” rating in a research note on Thursday, July 25th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $105.00 target price on shares of Viking Therapeutics in a research report on Thursday, September 12th. One investment analyst has rated the stock with a sell rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $109.80.

Viking Therapeutics Trading Down 0.5 %

Shares of Viking Therapeutics stock opened at $68.48 on Friday. The firm’s 50 day moving average is $64.76 and its 200 day moving average is $61.89. The firm has a market capitalization of $7.63 billion, a PE ratio of -73.63 and a beta of 1.00. Viking Therapeutics, Inc. has a 1 year low of $9.34 and a 1 year high of $99.41.

Viking Therapeutics (NASDAQ:VKTX) last posted its earnings results on Wednesday, October 23rd. The biotechnology company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.02. During the same quarter in the prior year, the firm posted ($0.23) EPS. As a group, research analysts anticipate that Viking Therapeutics, Inc. will post -0.98 earnings per share for the current year.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.